Equities research analysts expect Exelixis, Inc. (NASDAQ:EXEL) to post earnings per share of $0.20 for the current quarter, according to Zacks. Five analysts have issued estimates for Exelixis’ earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at $0.16. Exelixis posted earnings of $0.41 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 51.2%. The firm is expected to issue its next quarterly earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Exelixis will report full year earnings of $0.93 per share for the current year, with EPS estimates ranging from $0.80 to $0.99. For the next year, analysts expect that the business will post earnings of $1.06 per share, with EPS estimates ranging from $0.82 to $1.15. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Exelixis.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.23 by $0.02. The business had revenue of $240.28 million during the quarter, compared to analyst estimates of $226.97 million. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The company’s revenue for the quarter was up 29.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.31 earnings per share.
EXEL has been the subject of several recent research reports. BidaskClub lowered Exelixis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. ValuEngine raised Exelixis from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 10th. BMO Capital Markets lowered their price objective on Exelixis from $23.00 to $19.00 and set a “market perform” rating for the company in a research report on Tuesday, October 8th. Guggenheim lowered their price target on Exelixis from $33.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Cowen set a $25.00 price target on Exelixis and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Exelixis presently has an average rating of “Hold” and an average target price of $27.13.
In other news, CEO Michael Morrissey sold 26,364 shares of Exelixis stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $17.66, for a total value of $465,588.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director George A. Scangos sold 40,000 shares of Exelixis stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $20.59, for a total value of $823,600.00. Following the completion of the transaction, the director now directly owns 1,134,081 shares of the company’s stock, valued at approximately $23,350,727.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 350,974 shares of company stock valued at $7,005,921. 4.50% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in Exelixis by 40.7% in the 2nd quarter. Renaissance Technologies LLC now owns 13,454,473 shares of the biotechnology company’s stock worth $287,522,000 after buying an additional 3,889,200 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Exelixis by 20.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,143,165 shares of the biotechnology company’s stock worth $131,279,000 after buying an additional 1,051,976 shares in the last quarter. First Trust Advisors LP increased its holdings in Exelixis by 8.0% in the 2nd quarter. First Trust Advisors LP now owns 5,865,637 shares of the biotechnology company’s stock worth $125,349,000 after buying an additional 433,202 shares in the last quarter. Orbimed Advisors LLC increased its holdings in Exelixis by 39.7% in the 2nd quarter. Orbimed Advisors LLC now owns 3,912,900 shares of the biotechnology company’s stock worth $83,619,000 after buying an additional 1,111,000 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Exelixis by 1.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,781,502 shares of the biotechnology company’s stock worth $80,810,000 after buying an additional 71,830 shares in the last quarter. 77.41% of the stock is owned by hedge funds and other institutional investors.
Exelixis stock traded up $0.19 on Wednesday, hitting $16.98. 59,625 shares of the stock traded hands, compared to its average volume of 2,539,121. The company has a current ratio of 8.64, a quick ratio of 8.53 and a debt-to-equity ratio of 0.02. The firm has a market cap of $5.00 billion, a P/E ratio of 11.84 and a beta of 1.81. The business’s fifty day simple moving average is $18.54 and its 200 day simple moving average is $20.39. Exelixis has a 1 year low of $13.42 and a 1 year high of $25.31.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.